

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CSPC PHARMACEUTICAL GROUP LIMITED

石藥集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock code: 1093)

VOLUNTARY ANNOUNCEMENT

BIOLOGIC LICENSE APPLICATION OF BATOCLIMAB (HBM9161) ACCEPTED BY THE NMPA

The board of directors (the “**Board**”) of CSPC Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that the National Medical Products Administration (NMPA) of the People’s Republic of China has officially accepted the biologic license application of Batoclimab (HBM9161), an in-licensed product of CSPC NBP Pharmaceutical Co. Ltd* (石藥集團恩必普藥業有限公司) (“**NBP**”), a subsidiary of the Company, for the treatment of generalised myasthenia gravis (“**gMG**”).

Batoclimab (HBM9161) is a product to treat multiple pathogenic IgG-mediated autoimmune diseases with significant unmet medical needs. gMG is among the first of such multiple indications and this therapy received the Breakthrough Therapy Certificate from the NMPA in early 2021 and released the positive topline data of its Phase II clinical trial in July 2021. In October 2022, NBP entered into a license agreement with Harbour Biomed (Shanghai) Co., Ltd. to obtain the development, manufacture and commercialization rights of Batoclimab (HBM9161) in Greater China. In March 2023, Batoclimab (HBM9161) for the treatment of gMG demonstrated positive topline results in its Phase III clinical trial, meeting primary efficacy endpoint as well as key secondary endpoints with a favourable safety profile.

Based on the characteristics of Batoclimab’s mechanism of action and the clinical data available, the Group plans to continue its development in other indications of autoimmune diseases.

By Order of the Board
CSPC Pharmaceutical Group Limited
CAI Dongchen
Chairman

Hong Kong, 29 June 2023

As at the date of this announcement, the Board comprises Mr. CAI Dongchen, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. PAN Weidong, Mr. WANG Huaiyu, Dr. LI Chunlei, Dr. WANG Qingxi, Mr. CHAK Kin Man and Dr. JIANG Hao as executive directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as independent non-executive directors.

* *For identification purposes only*